CARsgen Financial Statements From 2010 to 2025
| CRTHF Stock | USD 2.20 1.44 189.47% |
Check CARsgen Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CARsgen Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . CARsgen financial statements analysis is a perfect complement when working with CARsgen Therapeutics Valuation or Volatility modules.
CARsgen |
CARsgen Therapeutics Holdings Company Shares Outstanding Analysis
CARsgen Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current CARsgen Therapeutics Shares Outstanding | 570.28 M |
Most of CARsgen Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CARsgen Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, CARsgen Therapeutics Holdings has 570.28 M of shares currently outstending. This is 215.88% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. This indicator is about the same for all United States stocks average (which is currently at 5.7181967952E8).
CARsgen Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CARsgen Therapeutics's current stock value. Our valuation model uses many indicators to compare CARsgen Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CARsgen Therapeutics competition to find correlations between indicators driving CARsgen Therapeutics's intrinsic value. More Info.CARsgen Therapeutics Holdings is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CARsgen Therapeutics' earnings, one of the primary drivers of an investment's value.About CARsgen Therapeutics Financial Statements
CARsgen Therapeutics stakeholders use historical fundamental indicators, such as CARsgen Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although CARsgen Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in CARsgen Therapeutics' assets and liabilities are reflected in the revenues and expenses on CARsgen Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CARsgen Therapeutics Holdings. Please read more on our technical analysis and fundamental analysis pages.
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company was founded in 2014 and is headquartered in Shanghai, China. Carsgen Therapeutics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in CARsgen Pink Sheet
CARsgen Therapeutics financial ratios help investors to determine whether CARsgen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CARsgen with respect to the benefits of owning CARsgen Therapeutics security.